Massachusetts Financial Services Co. MA Has $930,000 Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Massachusetts Financial Services Co. MA lowered its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRXFree Report) by 3.7% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 79,563 shares of the biopharmaceutical company’s stock after selling 3,049 shares during the period. Massachusetts Financial Services Co. MA owned about 0.07% of Catalyst Pharmaceuticals worth $930,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in CPRX. Advisory Services Network LLC boosted its stake in Catalyst Pharmaceuticals by 260.2% in the 1st quarter. Advisory Services Network LLC now owns 1,801 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 1,301 shares during the period. VisionPoint Advisory Group LLC acquired a new position in Catalyst Pharmaceuticals in the 2nd quarter worth $43,000. FMR LLC boosted its stake in Catalyst Pharmaceuticals by 24.2% in the 2nd quarter. FMR LLC now owns 4,218 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 822 shares during the period. Covestor Ltd boosted its stake in Catalyst Pharmaceuticals by 768.0% in the 1st quarter. Covestor Ltd now owns 4,878 shares of the biopharmaceutical company’s stock worth $40,000 after purchasing an additional 4,316 shares during the period. Finally, Quantbot Technologies LP acquired a new position in Catalyst Pharmaceuticals in the 1st quarter worth $62,000. Institutional investors own 77.27% of the company’s stock.

Catalyst Pharmaceuticals Price Performance

Shares of CPRX stock opened at $13.64 on Tuesday. The firm has a 50 day moving average price of $14.87 and a two-hundred day moving average price of $13.86. The company has a market capitalization of $1.60 billion, a PE ratio of 26.23 and a beta of 0.93. Catalyst Pharmaceuticals, Inc. has a 12-month low of $11.09 and a 12-month high of $18.22.

Insiders Place Their Bets

In other Catalyst Pharmaceuticals news, CFO Alicia Grande sold 40,000 shares of the firm’s stock in a transaction that occurred on Friday, December 8th. The shares were sold at an average price of $14.28, for a total transaction of $571,200.00. Following the completion of the sale, the chief financial officer now directly owns 50,557 shares in the company, valued at $721,953.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CFO Alicia Grande sold 40,000 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Friday, December 8th. The shares were sold at an average price of $14.28, for a total value of $571,200.00. Following the completion of the sale, the chief financial officer now directly owns 50,557 shares in the company, valued at $721,953.96. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director David S. Tierney sold 50,000 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $13.32, for a total transaction of $666,000.00. Following the completion of the sale, the director now owns 333,541 shares of the company’s stock, valued at $4,442,766.12. The disclosure for this sale can be found here. Insiders sold 190,000 shares of company stock worth $2,632,400 over the last three months. Insiders own 12.10% of the company’s stock.

Wall Street Analyst Weigh In

CPRX has been the subject of a number of research analyst reports. TheStreet lowered shares of Catalyst Pharmaceuticals from a “b” rating to a “c+” rating in a research note on Thursday, November 9th. Oppenheimer began coverage on Catalyst Pharmaceuticals in a report on Thursday, December 21st. They issued an “outperform” rating and a $30.00 price objective for the company. One investment analyst has rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $25.80.

View Our Latest Stock Analysis on Catalyst Pharmaceuticals

About Catalyst Pharmaceuticals

(Free Report)

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.

Read More

Want to see what other hedge funds are holding CPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRXFree Report).

Institutional Ownership by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.